Certolizumab pegol is effective for chronic plaque psoriasis across patient subgroups: A pooled subanalysis from ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT)

被引：0

作者：

Reich, Kristian ^{[1
]}

Gottlieb, Alice B. ^{[2
]}

Blauvelt, Andrew ^{[3
]}

Sofen, Howard ^{[4
]}

Weglowska, Jolanta ^{[5
]}

Augustin, Matthias ^{[6
]}

Poulin, Yves ^{[7
]}

Burge, Janice Drewof Danil ^{[8
]}

Peterson, Luke ^{[9
]}

Rolleri, Robert ^{[9
]}

Leonardi, Craig ^{[10
]}

机构：

[1] SCIderm Res Inst & Dermatol Hamburg, Hamburg, Germany

[2] New York Med Coll, Valhalla, NY 10595 USA

[3] Oregon Med Res Ctr, Portland, OR USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[5] Niepubl Zaklad Opieki Zdrowotney MultiMed, Bialystok, Poland

[6] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[7] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

[8] Dermira Inc, Menlo Pk, CA USA

[9] UCB BioSci Inc, Raleigh, NC USA

[10] Cent Dermatol, St Louis, MO USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

7692

引用

页码：AB66 / AB66

页数：1

共 26 条

[1] Certolizumab pegol is effective for chronic plaque psoriasis regardless of previous exposure to systemic therapy: A pooled subanalysis of ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT)
Blauvelt, Andrew
Reich, Kristian
Lebwohl, Mark
Paul, Carle
Leonardi, Craig
Thaci, Diamant
Piguet, Vincent
Drew, Janice
Burge, Daniel
Peterson, Luke
Rolleri, Robet
Lacour, Jean-Philippe
Gottlieb, Alice B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB67 - AB67
[2] A pooled subanalysis of the efficacy of certolizumab pegol in patients with self-reported psoriatic arthritis in ongoing phase 3 psoriasis studies (CIMPASI-1, CIMPASI-2, and CIMPACT)
Gottlieb, Alice B.
Merola, Joseph F.
Reich, Kristian
Thaci, Diamant
Coates, Laura
Drew, Janice
Burge, Daniel
Peteson, Luke
Arendt, Catherine
Kavanaugh, Arthur
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB19 - AB19
[3] Certolizumab pegol for treatment of plaque psoriasis: pooled efficacy outcomes across baseline Psoriasis Area and Severity Index subgroups (CIMPASI-1 and CIMPASI-2)
Spelman, Lynda
Foley, Peter
Baker, Christopher
Tilt, Nicola
Lanzafame, Alfred
McDougall, Todd
Penas, Pablo Fernandez
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 12 - 13
[4] Durability of response in plaque psoriasis patients receiving certolizumab pegol over 48 weeks in phase 3 studies: CIMPASI-1, CIMPASI-2, CIMPACT
Augustin, M.
Weglowska, J.
Lebwohl, M.
Paul, C.
Piguet, V.
Sofen, H.
Blauvelt, A.
Peterson, L.
Rolleri, R.
Reich, K.
Thaci, D.
Leonardi, C.
Poulin, Y.
Arendt, C.
Gottlieb, A.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 14 - 15
[5] Certolizumab pegol for plaque psoriasis: 2-year efficacy results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2)
Gordon, K.
Reich, K.
Blauvelt, A.
Thaci, D.
Leonardi, C.
Poulin, Y.
Boehnlein, M.
Kavanagh, S.
Arendt, C.
Gottlieb, A. B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB179 - AB179
[6] Durability of response in plaque psoriasis patients treated with certolizumab pegol: Two year data from the CIMPASI-1 and CIMPASI-2 phase 3 trials
Gordon, Kenneth
Reich, Kristian
Blauvelt, Andrew
Thaci, Diamant
Leonardi, Craig
Poulin, Yves
Boehnlein, Marion
Kavanagh, Sarah
Arendt, Catherine
Gottlieb, Alice B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB195 - AB195
[7] Long Lasting Efficacy in Patients with Plaque- Psoriasis under Treatment with Certolizumab Pegol for 48 Weeks: Pooled Results from Multicentric, Randomized, Placebo Controlled Phase III Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)
Augustin, M.
Weglowska, J.
Lebwohl, M.
Paul, C.
Piguet, V
Sofen, H.
Blauvelt, A.
Peterson, L.
Rolleri, R.
Reich, K.
Thaci, D.
Leonardi, C.
Poulin, Y.
Arendt, C.
Gottlieb, A.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 119 - 120
[8] Reductions in absolute PASI over 144 weeks of treatment with certolizumab pegol in patients with plaque psoriasis: Pooled analysis from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Gottlieb, Alice
Blauvelt, Andrew
Thaci, Diamant
Poulin, Yves
Brock, Fiona
Arendt, Catherine
Boehnlein, Marion
Reich, Kristian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB138 - AB138
[9] Safety of certolizumab pegol in plaque psoriasis: pooled 96-week data from three phase 3, multicenter, randomized, placebo -controlled studies (CIMPASI-1, CIMPASI-z and CIMPACT)
Blauvelt, A.
Strober, B.
Langley, R.
Kavanagh, S.
Arendt, C.
Boehnlein, M.
Lebwohl, M.
Reich, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 21 - 22
[10] Durable efficacy of certolizumab pegol dosed at 400 mg every two weeks over 128 weeks in patients with plaque psoriasis enrolled in three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT)
Gordon, Ken
Warren, Richard B.
Gottlieb, Alice B.
Blauvelt, Andrew
Thaci, Diamant
Poulin, Yves
Boehnlein, Marion
Brock, Fiona
Arendt, Catherine
Reich, Kristian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB139 - AB139

← 1 2 3 →